Cannabis use and cannabis use disorder among older adults in the USA.
Abstract
BACKGROUND AND AIMS
Cannabis use is increasing among older adults in the United States (US); however, little is known regarding details of use or cannabis use disorder (CUD) in this population. This study aimed to describe cannabis use and CUD among older adults in the US.
DESIGN
Secondary analysis of the 2021-2024 National Survey on Drug Use and Health, an annual cross-sectional nationally representative sample of noninstitutionalized people aged ≥12 living in the US.
SETTING
United States.
PARTICIPANTS
Noninstitutionalized individuals age ≥65 years (unweighted N = 21 189).
MEASUREMENTS
We estimated the prevalence of cannabis use by recency (any past 12-month use and past 30-day use), meeting two or more Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 CUD criteria, as well as CUD severity and individual CUD criteria among adults age ≥65 years who used cannabis in the past 12 months. Cannabis use and CUD were compared across sociodemographic and health-related characteristics, modality of use (2022-2024 only), and individual CUD criteria. Bivariable generalized linear regression models estimated the relative risk (RR) of CUD for older adults with each characteristic and modality of cannabis use.
RESULTS
An estimated 8.9% of older adults used cannabis in the past 12 months, and among them, 11.4% met criteria for CUD (76.0% mild, 20.1% moderate, and 3.9% severe CUD). Smoking was the most common modality of past 12-month use (65.8%), followed by eating or drinking…
Read the paper
Related studies
- Tobacco and COPD: presenting the World Health Organization (WHO) Tobacco Knowledge Summary
- Comparative effects of e-cigarette smoking on periodontal status, salivary pH, and cotinine levels
- Association between exposure to environmental pollutants and increased oral health risks, a comprehensive review
- Influence of gestational window on offspring vascular health in rodents with in utero exposure to electronic cigarettes
- Natural products as kinase inhibitors in lung cancer: molecular mechanisms, therapeutic potential, and clinical trials
- Nicotine in electronic cigarettes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.